2002, 92% of these prescriptions were for SGA medications. 9 A cross-sectional US study reported that antipsychotic medication was prescribed to more than two million children and adolescent outpatients between 2003 and 2004. 10 Prescription rates have also increased in the United Kingdom (UK): between 1992 and 2005 the prevalence of antipsychotic use in those aged 0 to 18 almost doubled from 0.39 to 0.77 users per 1000 patientyears (U/1000PY). Most notably, there was almost a three-fold increase in the use of antipsychotics in children aged 7 to 12 years from 0.23 to 0.61 U/1000PY. 11 To date no Australian studies have examined national trends in antipsychotic medications dispensed to children and youth. In Australia, the cost of some SGA medications are subsidised for the treatment of schizophrenia, bipolar disorder and autism. The aim of this study was to examine the national trends in dispensed use of government-subsidised SGAs to children and youth aged less than 25 years between 2002 and 2007. Furthermore, we highlight the deficiencies in available data in order to encourage more accurate monitoring of psychotropic medication prescribing to children and adolescents.
Methods
In 2008 we requested data on the number of dispensed prescriptions in Australia for SGA medications from the Australian Government's Department of Health and Ageing. We obtained the Medicare Australia records of prescriptions submitted for payment of a subsidy under the Pharmaceutical Benefits and Repatriation Pharmaceutical Benefits Schemes (PBS/RPBS). 12 From these data, we published the trends in prescribing of SGAs in the adult population. 13 In 2011, we requested more recent data for children and youth under 25 years but this request was refused. Hence the data presented here is the best available from the Australian Government as of 2012. Although all SGAs of interest were subsidised for those whose diagnoses met the authority restrictions, it was also possible to obtain a private prescription to use these drugs to treat other disorders (i.e. anxiety, depression, disruptive behavioural disorders) at full cost to the patient. Medicare Australia did not collect data on private prescriptions and so the gender and age of persons receiving private scripts for these drugs were not included in our study.
De-identified data on subsidised scripts included details of the drug product dispensed and information on the patient's gender and age. The use of prescription medicines dispensed to inpatients in public hospitals was not available.
The quantity of each drug dispensed was standardised using the defined daily dose (DDD) per 1000 population per day (DDD/1000 population/day). The DDD, established by the World Health Organisation Collaborating Centre for Drug Statistics Methodology, corresponds to an estimated average daily dose used for a medication's principal indication in adults. 14 
Results
According to the available data, dispensed use of SGAs in children aged 0-14 years remained stable over the fiveyear study period (Figure 1 ). In 2007, total dispensed use of SGAs in children was 0.25 DDD/1000 population/day. This equates to fewer than three children in 10,000 persons younger than 15 years receiving a standard adult dose of medication each day. Risperidone was the most commonly dispensed drug between 2002 and 2007, accounting for 52% of all SGAs dispensed to children. Dispensed SGA use in Australian youth (15-24 years) was approximately 24-fold higher than in children ( In Australian youth, males aged between 20 and 24 had the highest dispensed SGA use: 6.48 DDD/1000 population/day in 2007 ( Figure 4 ). This equates to six in every 1000 Australian males aged 20 to 24 years being dispensed a standard adult dose of a subsidised SGA. In those aged between 15-19 years in 2007, there was approximately four times more dispensed SGA use in males than females, whereas in youth aged between 20 and 24 there was a twofold difference between males and females (Figure 4 ).
Discussion
The total dispensed use of subsidised SGAs by children less than 15 years of age remained stable between 2002 and 2007. This is in contrast to studies reporting increased rates of antipsychotic medication use among children and adolescents in the US, the UK, Iceland and Germany. 9, 11, 16, 17 The most likely explanation is that the available data captured only publicly subsidised prescriptions for SGAs that were used for the approved indications of schizophrenia, bipolar disorder and, in 2007, autism. In privately insured children (2-18 years) in the US, SGAs were most commonly prescribed for disruptive behaviour disorders (67%), mood disorders (65%) and anxiety disorders (43%). 18 SGAs are not subsidised for any of these indications in Australia.
Despite the increase in dispensed use of SGAs in children aged 10 to 14 years of both sexes, there remained a very low rate of dispensing at the end of the study period. In 2007, approximately 34 in every 100,000 Australian children (0.034%) received a defined daily (adult) dose of subsidised SGA medication. By comparison, during 2007, approximately 700 in every 100,000 Australian children under 14 years were dispensed a stimulant. 19 Although there are no Australian prevalence studies of childhood schizophrenia, those from other countries have reported the prevalence rate of schizophrenia in children under 15 years to be less than 10 in 100,000. 20, 21 The limited dispensed use of SGAs under PBS subsidy is commensurate with the very low prevalence of schizophrenia in children.
This study highlights the deficiencies of the pharmacoepidemiology data that we accessed. Surprisingly in Australia, a developed nation with a sophisticated publicly subsidised health system, there are major limitations in accessing the available data. It is almost certain that there were a substantial number of prescriptions for SGAs in children for the management of disruptive behaviours . 18, 22 Although 92% of all SGA prescriptions in Australia are government subsidised, 13 we cannot calculate the proportion of private prescriptions dispensed to children and adolescents. We could not determine other characteristics of children and youth prescribed SGAs beyond gender and age. There was no information on the indications for SGA prescribing and on whether they were co-prescribed with other psychotropic medications. Dispensed use may not reflect actual medication consumption. As the DDDs are standardised to the maintenance dose in adults, it is likely that the lower dose of medication prescribed to children (compared to adults) contributes, in part, to the very low rates of dispensed use. Therefore, the data presented here, especially for young children, are likely to substantially underestimate actual use. Finally, it is a concern that we were unable to access more recent data from the Australian Government Department of Health and Ageing.
This study emphasises the need to collect and make available more comprehensive data (i.e. subsidised and non-subsidised) on the use of all medications in children and young people in Australia. Access to these would improve monitoring of prescribing trends to children and adolescents and assist in supporting the quality use of medicines in this population.
